12:00 AM
 | 
Nov 10, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Hematide: Extension study data

The partners announced interim pooled data from 182 CKD patients in ongoing extensions of 2 open-label Phase II trials (Study 09 and 10) of Hematide. The compound, dosed once every 4 weeks, maintained mean hemoglobin concentrations...

Read the full 160 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >